Q-omics provides the consensus-scored NOTO profile across patient tissues and cancer cell-line models. NOTO expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NOTO is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, NOTO RNA expression shows 9,579 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where NOTO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOTO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOTO survival associations across molecular data types. NOTO RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOTO RNA expression–survival associations across cancer types. High NOTO expression shows unfavorable associations in COAD, SKCM and CHOL, but favorable associations in LUAD, OV and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for NOTO RNA expression.
This table summarizes NOTO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NOTO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOTO shows lower tumor expression in COAD, READ and KICH and higher tumor expression in HNSC, THCA and LUAD. The COAD box plot shows higher NOTO RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p < 0.001).
This table shows molecular features associated with NOTO in patient tissues and cancer cell lines. In patient samples, NOTO shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NOTO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OVARY.
